Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT071 in High-Risk Newly Diagnosed Multiple Myeloma
NCT06407947Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT071 in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Adverse Events up to 24 months, Overall Response Rate up to 24 months and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
CT071
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06407947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407947.